Clinical Scorecard: Influence of RAS Mutation Status on Early Disease Progression in Patients with Initially Unresectable Colorectal Liver Metastases Receiving Conversion Therapy: A Retrospective Study

At a Glance

Key Highlights

• 44.8% of patients achieved successful conversion.
• RAS-mutant patients had a higher early progression/recurrence rate (41.2% vs. 19.6%).
• RAS mutation independently associated with early progression/recurrence (OR: 3.546).
• Higher early progression rate in failed conversion patients with RAS mutations (36.7% vs. 13.0%).
• No significant difference in early recurrence rates among successfully converted patients by RAS status.

Guideline-Based Recommendations

Diagnosis

• Histological confirmation of colorectal adenocarcinoma with proficient mismatch repair (pMMR).
• RAS mutation status determined by Next-Generation Sequencing (NGS) or Polymerase Chain Reaction (PCR).

Management

• Individualized treatment strategies based on RAS mutation status.
• Multidisciplinary team consensus for treatment and resectability.

Monitoring & Follow-up

• Surveillance strategies may be individualized based on RAS mutation status.

Risks

• Higher risk of early progression/recurrence in RAS-mutant patients.

Patient & Prescribing Data

194 patients with initially unresectable, pMMR CRLM.

Targeted therapy selected based on molecular testing results and RAS status.

Clinical Best Practices

• Utilize RAS mutation status to guide targeted therapy decisions.
• Monitor for early progression/recurrence in RAS-mutant patients.

Related Resources & Content

• STROBE Statement Guidelines